Antibody-secreting B cells in HIV infection

Current Opinion in HIV and AIDS

Volumn 4, Issue 5, 2009, Pages 426-430

  Doria Rose, Nicole A ^a   Connors, Mark ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibodies; B cell; Envelope; Enzyme linked immunosorbent spot; HIV

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CELL PH; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN GENE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SECRETORY CELL;

AIDS VACCINES; B-LYMPHOCYTES; FLOW CYTOMETRY; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; LYMPHOCYTE SUBSETS;

EID: 69549091675     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832d9fac     Document Type: Review

References (38)

1. Moore JP, Cao Y, Ho DD, Koup RA. Development of the antigp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68:5142-5155. (Pubitemid 24226583)
2. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149. (Pubitemid 36418171)
3. Doria-Rose NA, Klein RM, Manion MM, et al. Frequency and phenotype of HIV envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83:188-199. This study is the first to use labeling of HIV Env-specific cells for flow cytometric characterization of B-cell phenotype. Plasmablasts are identified as an expanded population in HIV patients and account for most HIV-specific ASC.
4. Lane HC, Masur H, Edgard LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453-458.
5. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245. A detailed review of B-cell abnormalities and their possible consequences in HIV-infected patients.
6. Morrow M, Valentin A, Little R, et al. A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2008; 24:621-633. (Pubitemid 351571037)
7. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205:1797-1805. This study identifies tissue-like memory cells as a major B-cell subset in HIV-infected patients. These cells, which are enriched for HIV specificity, have functional defects including poor in-vitro proliferation and a truncated history of cell divisions and somatic hypermutation.
8. Cagigi A, Mowafi F, Phuong Dang LV, et al. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood 2008; 112:4401-4410.
9. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008; 197:572-579. This study shows partial restoration of B-cell subsets after HAART. (Pubitemid 351321535)
10. Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178:8212-8220. (Pubitemid 46898094)
11. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007; 21:1747-1752.
12. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659-666.
13. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and noninfected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-2457. (Pubitemid 46389429)
14. Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Curr HIV Res 2004; 2:293-299 (Pubitemid 39242959)
15. Rivas P, Herrero MD, Puente S, et al. Immunizations in HIV-infected adults. AIDS Rev 2007; 9:173-187.
16. + T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 2000; 182:435-441.
17. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442-1450. (Pubitemid 40563355)
18. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998; 188:233-245. (Pubitemid 28357752)
19. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992; 89:561-566.
20. Fondere JM, Huguet MF, Yssel H, et al. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS 2003; 17:2323-2330. (Pubitemid 38147017)
21. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20:972-988. (Pubitemid 39369704)
22. Yang X, Lee J, Mahony EM, et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002; 76:4634-4642. (Pubitemid 34309599)
23. Forsell MN, Dey B, Morner A, et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog 2008; 4:e1000171.
24. Scheid JF, Mouquet H, Feldhahn N, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009; 343:65-67.
25. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640. The authors isolated hundreds of HIV Env-specific antibodies by sorting Env-labeled B cells and recovering the IgG genes. Epitopes and neutralization activity are catalogued in detail.
26. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-671. (Pubitemid 351769295)
27. Smith K, Garman L, Wrammert J, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009; 4:372-384. This study provides a detailed method for recovering IgG genes from FACS-sorted ASC.
28. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
29. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304:104-107. (Pubitemid 38451466)
30. Guan Y, Sajadi MM, Kamin-Lewis R, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 2009; 106:3952-3957.
31. Tiller T, Meffre E, Yurasov S, et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-124. This study provides a detailed method for recovering IgG genes from FACS-sorted B cells. (Pubitemid 350235462)
32. Mascola JR, D'Souza P, Gilbert P, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79:10103-10107. (Pubitemid 41098551)
33. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651-11668.
34. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034. (Pubitemid 47517505)
35. Li Y, Svehla K, Louder MK, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045-1059.
36. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83:757-769.
37. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377. (Pubitemid 37075812)
38. Gorny MK, Wang XH, Williams C, et al. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol Immunol 2009; 46:917-926. This study examines VH gene usage in mAbs specific for various HIV Env epitopes.